[1] Fokkens W, Desrosiers M, Harvey R, et al. EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis[J]. Rhinology, 2019, 57(3): 162-168. [2] Shi J B, Fu Q L, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities[J]. Allergy, 2015, 70(5): 533-539. [3] Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J]. J Allergy Clin Immunol, 2016, 137(5):1449-1456. [4] Wang X D, Zhang N, Bo M Y, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania[J]. J Allergy Clin Immunol, 2016, 138(5): 1344-1353. [5] Turner J H, Chandra R K, Li P, et al. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines[J]. J Allergy Clin Immunol, 2018, 141(5): 1895-1897. [6] 张海波, 张宇玲, 赵丽敏, 等. 巨噬细胞在慢性鼻窦炎伴鼻息肉中的研究进展[J]. 国际耳鼻咽喉头颈外科杂志, 2020, 44(4): 221-224, 236. [7] Hao D X, Li Y S, Shi J, et al. Baicalin alleviates chronic obstructive pulmonary disease through regulation of HSP72-mediated JNK pathway[J]. Mol Med, 2021, 27(1): 53. [8] Zhou T, Zhang A J, Kuang G, et al. Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting β-catenin signaling[J]. Oncol Rep, 2017, 38(6): 3599-3607. [9] Lu L W, Zhang M F, Wang X Y, et al. Baicalein enhances the antitumor efficacy of docetaxel on nonsmall cell lung cancer in a β-catenin-dependent manner[J]. Phytother Res, 2020, 34(1): 104-117. [10] Zhao H, Li C D, Li L N, et al. Baicalin alleviates bleomycin-induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway[J]. Mol Med Rep, 2020, 21(6): 2321-2334. [11] Liang W, Huang X B, Chen W Q. The effects of baicalin and baicalein on cerebral ischemia: a review[J]. Aging Dis, 2017, 8(6): 850-867. [12] Lin C, Tsai F J, Hsu Y M, et al. Study of baicalin toward COVID-19 treatment: in silico target analysis and in vitro inhibitory effects on SARS-CoV-2 proteases[J]. Biomed Hub, 2021, 6(3): 122-137. [13] Moghaddam E, Teoh B T, Sam S S, et al. Baicalin, a metabolite of baicalein with antiviral activity against dengue virus[J]. Sci Rep, 2014, 4: 5452. [14] Bui T T, Piao C H, Song C H, et al. Baicalein, wogonin, and Scutellaria baicalensis ethanol extract alleviate ovalbumin-induced allergic airway inflammation and mast cell-mediated anaphylactic shock by regulation of Th1/Th2 imbalance and histamine release[J]. Anat Cell Biol, 2017, 50(2): 124-134. [15] Yoshida K, Takabayashi T, Kaneko A, et al. Baicalin suppresses type 2 immunity through breaking off the interplay between mast cell and airway epithelial cell[J]. J Ethnopharmacol, 2021, 267: 113492. [16] Li J, Lin X Y, Liu X, et al. Baicalin regulates Treg/Th17 cell imbalance by inhibiting autophagy in allergic rhinitis[J]. Mol Immunol, 2020, 125: 162-171. [17] Chen S Z, Chen G R, Shu S, et al. Metabolomics analysis of baicalin on ovalbumin-sensitized allergic rhinitis rats[J]. R Soc Open Sci, 2019, 6(2): 181081. [18] Yang M, Zhu X Y, Fu F D, et al. Baicalin ameliorates inflammatory response in a mouse model of rhinosinusitis via regulating the Treg/Th17 balance[J]. Ear Nose Throat J, 2022, 101(2_suppl): 8S-16S. [19] Liu J Q, Wei Y, Luo Q L, et al. Baicalin attenuates inflammation in mice with OVA-induced asthma by inhibiting NF-κB and suppressing CCR7/CCL19/CCL21[J]. Int J Mol Med, 2016, 38(5): 1541-1548. |